CliffBio
small molecule

ARMONAIR RESPICLICK

FLUTICASONE PROPIONATE

Loss of exclusivityFebruary 2040latest FDA-listed patent expiry
CompanyTeva Pharmaceutical Industries →View the full company profile on CliffBio

Drug detail

Brand nameARMONAIR RESPICLICK
Active ingredientFLUTICASONE PROPIONATE
Strength0.113MG/INH
Dosage formPOWDER
RouteINHALATION
ModalitySmall molecule
FDA approvalJanuary 2017
Marketing statusDISCN

Listed patents

PatentExpiresType
11969544*PEDFebruary 2040—
11969544August 2039product
10195375*PEDAugust 2031—
10195375February 2031product

More from Teva Pharmaceutical Industries

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ARMONAIR RESPICLICK patent cliff — loss of exclusivity February 2040 | CliffBio